Journal of Clinical Endocrinology & Metabolism, Vol 78, 30-35, Copyright © 1994 by Endocrine Society

ARTICLES

Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropin-releasing hormone test

L Ibanez, N Potau, M Zampolli, R Virdis, M Gussinye, A Carrascosa, P Saenger and E Vicens-Calvet
Endocrinology Unit, Hospital Materno-Infantil Vall d'Hebron, Autonomous University, Barcelona, Spain.

The effects of a single injection (500 micrograms sc) of the GnRH agonist leuprolide acetate on gonadotropin secretion and those induced by a GnRH test were analyzed in 32 children (11 males and 21 females) referred for possible pubertal developmental disorders and in 9 prepubertal controls [group C; 4 males and 5 females; chronological age (CA), 7.4 +/- 1.2 yr]. The pituitary-gonadal secretory responses to the GnRH agonist were characterized in all subjects and in a control group in early puberty [10 females (Tanner breast stage II; CA, 11.3 +/- 1.1 yr) and 6 males (Tanner pubertal stage II; CA, 13.5 +/- 0.4 yr); group D]. Twelve girls (CA, 7.1 +/- 0.7 yr) presented with precocious breast development, 11 patients [6 boys (CA, 10.9 +/- 0.4 yr) and 5 girls (CA, 9.3 +/- 0.5 yr)] had advanced puberty and predicted adult heights below -2.0 SD score, and 9 patients [5 boys (CA, 14.6 +/- 0.3 yr) and 4 girls (CA, 14.4 +/- 1.1 yr)] had delayed puberty. Less than 6 months had elapsed since the appearance of pubertal signs in all patients with pubertal development. After a follow-up period of 12.9 +/- 2.0 months, 20 patients showed progression of pubertal signs (group A, progressive puberty), and in 12, puberty regressed or did not progress (group B, nonprogressive puberty). The results of hormonal tests in all patients were analyzed retrospectively according to their clinical outcome. Patients in group A had a mean plasma peak LH response significantly higher after leuprolide acetate stimulation than after GnRH challenge (13.1 +/- 0.2 vs. 7.3 +/- 0.9 IU/L; P < 0.003). Those in groups B and C had similar peak LH responses after both tests (3.3 +/- 0.2 vs. 3.1 +/- 0.4, and 1.5 +/- 0.1 vs. 1.8 +/- 0.4 IU/L, respectively). No differences in basal and poststimulated LH levels were found between boys and girls in the same group. In patients in groups A and D, LH consistently peaked 3 h postleuprolide acetate challenge; in those in groups B and C, the LH peak occurred 3-6 h postinjection. Maximal gonadal responses were elicited 24 h poststimulation. No overlap in poststimulated estradiol or testosterone values occurred between patients in groups A and D and those in groups B and C.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				C. P. Houk, A. R. Kunselman, and P. A. Lee Adequacy of a Single Unstimulated Luteinizing Hormone Level to Diagnose Central Precocious Puberty in Girls Pediatrics, June 1, 2009; 123(6): e1059 - e1063. [Abstract] [Full Text] [PDF]

				J.-C. Carel, E. A. Eugster, A. Rogol, L. Ghizzoni, M. R. Palmert, and on behalf of the members of the ESPE-LWPES GnRH An Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children Pediatrics, April 1, 2009; 123(4): e752 - e762. [Abstract] [Full Text] [PDF]

				T. Y. Segal, A. Mehta, A. Anazodo, P. C. Hindmarsh, and M. T. Dattani Role of Gonadotropin-Releasing Hormone and Human Chorionic Gonadotropin Stimulation Tests in Differentiating Patients with Hypogonadotropic Hypogonadism from Those with Constitutional Delay of Growth and Puberty J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 780 - 785. [Abstract] [Full Text] [PDF]

				S. E. Recabarren, T. Sir-Petermann, R. Rios, M. Maliqueo, B. Echiburu, R. Smith, P. Rojas-Garcia, M. Recabarren, and R. A. Rey Pituitary and Testicular Function in Sons of Women with Polycystic Ovary Syndrome from Infancy to Adulthood J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3318 - 3324. [Abstract] [Full Text] [PDF]

				E. A. Eugster, W. Clarke, G. B. Kletter, P. A. Lee, E. K. Neely, E. O. Reiter, P. Saenger, D. Shulman, L. Silverman, L. Flood, et al. Efficacy and Safety of Histrelin Subdermal Implant in Children with Central Precocious Puberty: A Multicenter Trial J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1697 - 1704. [Abstract] [Full Text] [PDF]

				L. Ibanez, C. Valls, K. Ong, D. B. Dunger, and F. de Zegher Metformin Therapy during Puberty Delays Menarche, Prolongs Pubertal Growth, and Augments Adult Height: A Randomized Study in Low-Birth-Weight Girls with Early-Normal Onset of Puberty J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2068 - 2073. [Abstract] [Full Text] [PDF]

				A. Badaru, D. M. Wilson, L. K. Bachrach, P. Fechner, L. M. Gandrud, E. Durham, K. Wintergerst, C. Chi, K. O. Klein, and E. K. Neely Sequential Comparisons of One-Month and Three-Month Depot Leuprolide Regimens in Central Precocious Puberty J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1862 - 1867. [Abstract] [Full Text] [PDF]

				T. S. Petermann, A. Cartes, M. Maliqueo, D. Vantman, C. Gutierrez, H. Toloza, B. Echiburu, and S.E. Recabarren Patterns of hormonal response to the GnRH agonist leuprolide in brothers of women with polycystic ovary syndrome: a pilot study Hum. Reprod., December 1, 2004; 19(12): 2742 - 2747. [Abstract] [Full Text] [PDF]

				L. Ibáñez, J. DiMartino-Nardi, N. Potau, and P. Saenger Premature Adrenarche--Normal Variant or Forerunner of Adult Disease? Endocr. Rev., December 1, 2000; 21(6): 671 - 696. [Abstract] [Full Text]

				L. Ibáñez, A. Ferrer, M. V. Marcos, F. R. Hierro, and F. de Zegher Early Puberty: Rapid Progression and Reduced Final Height in Girls With Low Birth Weight Pediatrics, November 1, 2000; 106(5): 72e - 72. [Abstract] [Full Text]